Tags

Type your tag names separated by a space and hit enter

Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study.
J Minim Invasive Gynecol. 2021 02; 28(2):297-306.e2.JM

Abstract

STUDY OBJECTIVE

To determine the prevalence and pattern of opioid use in endometriosis and the characteristics of patients prescribed an opioid using medical insurance claims data.

DESIGN

We performed a retrospective cohort analysis of data from the Truven MarketScan Commercial database for the period of January 1, 2011 to December 31, 2016.

SETTING

The Truven database includes inpatient, outpatient, and prescription claims covering more than 115 million unique individuals and over 36 million inpatient hospital discharges across multiple payer types and all 50 states.

PATIENTS

Women with endometriosis were defined as those with 1 inpatient or 2 outpatient codes for endometriosis.

INTERVENTIONS

No interventions were assigned. Women who filled an opioid prescription within 12 months of diagnosis were placed in the opioid cohort and women who did not fill an opioid prescription were placed in the nonopioid cohort.

MEASUREMENTS AND MAIN RESULTS

Baseline characteristics were evaluated 12 months preindex (date of the first diagnosis) and opioid use was assessed for 12 months after the index date. The dataset included 58 472 women with endometriosis. Of these, 61.7% filled an opioid prescription during the study period. More than 95% filled prescriptions for short-acting opioids (SAOs) only, 4.1% filled prescriptions for both SAOs and extended-release/long-acting opioids (LAOs), and 0.6% filled prescriptions for LAOs only. Patients who filled an opioid prescription had higher baseline comorbidities (especially gynecologic and chronic pain comorbidities) and endometriosis-related medication use compared with patients who did not fill an opioid prescription during the study period. Patients who filled both LAO and SAO prescriptions had the highest total days' supply of opioids, the proportion of days covered by prescriptions, and morphine equivalent daily dose. These patients also had the highest proportions of opioid switching and dose augmentation. Statistical trends in data were not substantially altered when analyses excluded patients with chronic pain comorbidities or surgical opioid prescriptions.

CONCLUSION

Although opioids are not a recommended treatment for endometriosis, more than half of our cohort filled an opioid prescription within 1 year after a first recorded diagnosis of endometriosis. Patients who filled an opioid prescription tended to use more endometriosis-related medications and have a higher comorbidity burden. Additional research is necessary to better understand the reasons and outcomes associated with opioid utilization in endometriosis and to determine if there is a more effective pain management treatment plan for patients taking opioids.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan (Dr. As-Sanie). Electronic address: sassanie@med.umich.edu.AbbVie Inc, Chicago, Illinois (Dr. Soliman).WCG Analgesic Solutions, Wayland, (Drs. Evans and Katz).Parexel International, Waltham, (Dr. Erpelding).Canopy Growth Corporation, Smiths Falls, Ontario, Canada (Dr. Lanier).WCG Analgesic Solutions, Wayland, (Drs. Evans and Katz); Department of Anesthesiology, Tufts University School of Medicine, Boston, Massachusetts (Dr. Katz).

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32531340

Citation

As-Sanie, Sawsan, et al. "Short-acting and Long-acting Opioids Utilization Among Women Diagnosed With Endometriosis in the United States: a Population-based Claims Study." Journal of Minimally Invasive Gynecology, vol. 28, no. 2, 2021, pp. 297-306.e2.
As-Sanie S, Soliman AM, Evans K, et al. Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study. J Minim Invasive Gynecol. 2021;28(2):297-306.e2.
As-Sanie, S., Soliman, A. M., Evans, K., Erpelding, N., Lanier, R. K., & Katz, N. P. (2021). Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study. Journal of Minimally Invasive Gynecology, 28(2), 297-e2. https://doi.org/10.1016/j.jmig.2020.05.029
As-Sanie S, et al. Short-acting and Long-acting Opioids Utilization Among Women Diagnosed With Endometriosis in the United States: a Population-based Claims Study. J Minim Invasive Gynecol. 2021;28(2):297-306.e2. PubMed PMID: 32531340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-acting and Long-acting Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A Population-based Claims Study. AU - As-Sanie,Sawsan, AU - Soliman,Ahmed M, AU - Evans,Kathryn, AU - Erpelding,Nathalie, AU - Lanier,Ryan K, AU - Katz,Nathaniel P, Y1 - 2020/06/09/ PY - 2020/01/17/received PY - 2020/05/28/revised PY - 2020/05/29/accepted PY - 2020/6/13/pubmed PY - 2021/5/4/medline PY - 2020/6/13/entrez KW - Endometriosis KW - Opioids KW - Pain SP - 297 EP - 306.e2 JF - Journal of minimally invasive gynecology JO - J Minim Invasive Gynecol VL - 28 IS - 2 N2 - STUDY OBJECTIVE: To determine the prevalence and pattern of opioid use in endometriosis and the characteristics of patients prescribed an opioid using medical insurance claims data. DESIGN: We performed a retrospective cohort analysis of data from the Truven MarketScan Commercial database for the period of January 1, 2011 to December 31, 2016. SETTING: The Truven database includes inpatient, outpatient, and prescription claims covering more than 115 million unique individuals and over 36 million inpatient hospital discharges across multiple payer types and all 50 states. PATIENTS: Women with endometriosis were defined as those with 1 inpatient or 2 outpatient codes for endometriosis. INTERVENTIONS: No interventions were assigned. Women who filled an opioid prescription within 12 months of diagnosis were placed in the opioid cohort and women who did not fill an opioid prescription were placed in the nonopioid cohort. MEASUREMENTS AND MAIN RESULTS: Baseline characteristics were evaluated 12 months preindex (date of the first diagnosis) and opioid use was assessed for 12 months after the index date. The dataset included 58 472 women with endometriosis. Of these, 61.7% filled an opioid prescription during the study period. More than 95% filled prescriptions for short-acting opioids (SAOs) only, 4.1% filled prescriptions for both SAOs and extended-release/long-acting opioids (LAOs), and 0.6% filled prescriptions for LAOs only. Patients who filled an opioid prescription had higher baseline comorbidities (especially gynecologic and chronic pain comorbidities) and endometriosis-related medication use compared with patients who did not fill an opioid prescription during the study period. Patients who filled both LAO and SAO prescriptions had the highest total days' supply of opioids, the proportion of days covered by prescriptions, and morphine equivalent daily dose. These patients also had the highest proportions of opioid switching and dose augmentation. Statistical trends in data were not substantially altered when analyses excluded patients with chronic pain comorbidities or surgical opioid prescriptions. CONCLUSION: Although opioids are not a recommended treatment for endometriosis, more than half of our cohort filled an opioid prescription within 1 year after a first recorded diagnosis of endometriosis. Patients who filled an opioid prescription tended to use more endometriosis-related medications and have a higher comorbidity burden. Additional research is necessary to better understand the reasons and outcomes associated with opioid utilization in endometriosis and to determine if there is a more effective pain management treatment plan for patients taking opioids. SN - 1553-4669 UR - https://www.unboundmedicine.com/medline/citation/32531340/Short_acting_and_Long_acting_Opioids_Utilization_among_Women_Diagnosed_with_Endometriosis_in_the_United_States:_A_Population_based_Claims_Study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1553-4650(20)30291-0 DB - PRIME DP - Unbound Medicine ER -